Clinical Trial Detail

NCT ID NCT02648477
Title Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors City of Hope Medical Center

Her2-receptor negative breast cancer

triple-receptor negative breast cancer


Letrozole + Pembrolizumab

Exemestane + Pembrolizumab

Anastrozole + Pembrolizumab

Doxorubicin + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST